Mereo BioPharma Group/$MREO
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Mereo BioPharma Group
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Ticker
$MREO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
36
ISIN
US5894921072
Website
MREO Metrics
BasicAdvanced
$456M
-
-$0.31
0.47
-
Price and volume
Market cap
$456M
Beta
0.47
52-week high
$5.02
52-week low
$1.58
Average daily volume
1.2M
Financial strength
Current ratio
8.923
Quick ratio
8.654
Total debt to equity
1.243
Interest coverage (TTM)
-38.15%
Profitability
EBITDA (TTM)
-46.733
Management effectiveness
Return on assets (TTM)
-47.59%
Return on equity (TTM)
-91.70%
Valuation
Price to book
7.6
Price to tangible book (TTM)
7.67
Price to free cash flow (TTM)
-13.036
Free cash flow yield (TTM)
-7.67%
Free cash flow per share (TTM)
-22.02%
Growth
Earnings per share change (TTM)
59.81%
3-year earnings per share growth (CAGR)
-7.54%
What the Analysts think about MREO
Analyst ratings (Buy, Hold, Sell) for Mereo BioPharma Group stock.
Bulls say / Bears say
Mereo BioPharma's lead product candidate, setrusumab, is progressing through Phase 3 trials for osteogenesis imperfecta, with a second interim analysis expected in mid-2025, potentially leading to regulatory approval and commercialization. (mereobiopharma.com)
The company has secured a partnership with Ultragenyx Pharmaceutical, which includes potential milestone payments of up to $245 million and royalties on commercial sales, providing significant financial support and validation. (globenewswire.com)
Mereo BioPharma's financial position is bolstered by a cash runway expected to fund operations into 2027, allowing the company to advance its clinical programs without immediate financing concerns. (mereobiopharma.com)
Mereo BioPharma reported a net loss of $43.3 million for the year ended December 31, 2024, indicating ongoing financial challenges and the need for successful commercialization of its pipeline to achieve profitability. (mereobiopharma.com)
The company's reliance on partnerships, such as with Ultragenyx, means that a significant portion of potential revenues will be shared, which could impact overall profitability. (globenewswire.com)
As a clinical-stage biopharmaceutical company, Mereo BioPharma faces inherent risks in drug development, including potential delays or failures in clinical trials, which could adversely affect its stock value. (sec.gov)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
MREO Financial Performance
Revenues and expenses
MREO Earnings Performance
Company profitability
MREO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mereo BioPharma Group stock?
Mereo BioPharma Group (MREO) has a market cap of $456M as of July 04, 2025.
What is the P/E ratio for Mereo BioPharma Group stock?
The price to earnings (P/E) ratio for Mereo BioPharma Group (MREO) stock is 0 as of July 04, 2025.
Does Mereo BioPharma Group stock pay dividends?
No, Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Mereo BioPharma Group dividend payment date?
Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders.
What is the beta indicator for Mereo BioPharma Group?
Mereo BioPharma Group (MREO) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.